Affichem Overview
- Year Founded
-
2002

- Status
-
Private
- Employees
-
9

- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Affichem General Information
Description
Developer of therapeutic molecules and theranostic markers designed to develop and commercialize innovative therapeutic molecules. The company eases the treatment of cancer and neurodegenerative diseases through its developed molecules in the field of cancer and neurodegenerative diseases, development, and commercialization of products for the pharmaceutical industry, helping patients with the treatment of cancers.
Contact Information
Website
www.affichem.comCorporate Office
- 9 Saint-joseph Street
- 31400 Toulouse
- France
Corporate Office
- 9 Saint-joseph Street
- 31400 Toulouse
- France
Affichem Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Secondary Transaction - Private | 01-Dec-2022 | Completed | Generating Revenue | |||
4. Grant | 29-Jun-2012 | Completed | Generating Revenue | |||
3. Grant | 07-Oct-2011 | Completed | Generating Revenue | |||
2. Angel (individual) | 17-Nov-2009 | $89.3K | $159K | Completed | Startup | |
1. Accelerator/Incubator | 01-Jun-2002 | $70.1K | $70.1K | Completed | Startup |
Affichem Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary |
Affichem Patents
Affichem Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20200016177-A1 | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof | Inactive | 22-Sep-2016 | ||
US-20230138400-A1 | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof | Pending | 22-Sep-2016 | ||
EP-3097904-A1 | Depigmenting agents to lighten the skin | Active | 29-May-2015 | ||
EP-3097904-B1 | Depigmenting agents to lighten the skin | Active | 29-May-2015 | ||
EP-3221467-A1 | Methods of diagnosing cancer and of predicting response of cancer to dendrogenin a treatment | Inactive | 17-Nov-2014 | C12Q1/6886 |
Affichem Signals
Affichem Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
European Commission | Government | |||
L'Agence Nationale de la Recherche | Government |
Affichem FAQs
-
When was Affichem founded?
Affichem was founded in 2002.
-
Where is Affichem headquartered?
Affichem is headquartered in Toulouse, France.
-
What is the size of Affichem?
Affichem has 9 total employees.
-
What industry is Affichem in?
Affichem’s primary industry is Biotechnology.
-
Is Affichem a private or public company?
Affichem is a Private company.
-
What is Affichem’s current revenue?
The current revenue for Affichem is
. -
How much funding has Affichem raised over time?
Affichem has raised $159K.
-
Who are Affichem’s investors?
European Commission and L'Agence Nationale de la Recherche have invested in Affichem.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »